Head and Neck Squamous Cell Carcinoma Clinical Trials in Chicago, Illinois

16 studies are recruiting for head and neck squamous cell carcinoma in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

   This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chem…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   John H Stroger Jr Hospital of Cook County, Chicago, Illinois

   Locations

   679 in total

   Run by

   ECOG-ACRIN Cancer Research Group

   See if you can join NCT02734537 on ClinicalTrials.gov

2. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Chicago Hospital, Chicago, Illinois

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06465069 on ClinicalTrials.gov

3. A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

   The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Northwestern University Feinberg School of Medicine, Chicago, Illinois

   Locations

   32 in total

   Run by

   Tempus AI

   See if you can join NCT06163534 on ClinicalTrials.gov

4. Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Northwestern University Feinberg School of Medicine /ID# 257378, Chicago, Illinois

   Locations

   54 in total

   Run by

   AbbVie

   See if you can join NCT06084481 on ClinicalTrials.gov

5. Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

   This phase II trial compares the effectiveness of adding BMX-001 to usual symptom management versus usual symptom management alone for reducing oral mucositis in patients who are receiving chemoradiation for head and neck cancer. Oral mucositis (inflammation and mouth sores) is a common side effect…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Northwestern University, Chicago, Illinois

   Locations

   153 in total

   Run by

   NRG Oncology

   See if you can join NCT06532279 on ClinicalTrials.gov

6. Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

   This phase III trial compares cetuxumab to chemotherapy, carboplatin and paclitaxel, with intensity modulated radiation therapy for the treatment of patients with head and neck cancer who are unable to receive cisplatin. Cetuximab is in a class of medications called monoclonal antibodies. It binds …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Northwestern University, Chicago, Illinois

   Locations

   63 in total

   Run by

   NRG Oncology

   See if you can join NCT07441681 on ClinicalTrials.gov

7. A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 monotherapy in adult patients with selected squamous solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Chicago Medical Center - Oncology, Chicago, Illinois

   Locations

   41 in total

   Run by

   Alentis Therapeutics AG

   See if you can join NCT06747585 on ClinicalTrials.gov

8. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Cell Carcinoma (HNSCC) is a solid tumor, a disease in which ca…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Illinois Hospital and Health Sciences System /ID# 251750, Chicago, Illinois

   Locations

   48 in total

   Run by

   AbbVie

   See if you can join NCT05005403 on ClinicalTrials.gov

9. A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

   This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Site 197, Chicago, Illinois

   Locations

   205 in total

   Run by

   Merus B.V.

   See if you can join NCT06525220 on ClinicalTrials.gov

10. A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

    By doing this study, the research team would like to learn if using a blood test that measures the amount of tumor DNA in blood can help guide how to use chemotherapy combined with immunotherapy for individuals with head and neck cancer. Using this blood test, the research team hopes to learn if in…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of Chicago Comprehensive Cancer Center, Chicago, Illinois

    Run by

    University of Chicago

    See if you can join NCT05420948 on ClinicalTrials.gov

11. High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

    This phase III trial tests if gabapentin can prevent the need for opiate pain medication for mouth sores (oral mucositis) in patients undergoing treatment with chemotherapy and radiation for squamous cell carcinoma of the head and neck region. Oral mucositis is a common side effect of radiation tre…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Advocate Illinois Masonic Medical Center, Chicago, Illinois

    Locations

    200 in total

    Run by

    Alliance for Clinical Trials in Oncology

    See if you can join NCT06992427 on ClinicalTrials.gov

12. Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer

    The purpose of this study is to evaluate the safety, tolerability and maximum tolerated dose of tislelizumab in combination with pamiparib plus chemoradiotherapy (chemotherapy and radiation) in individuals with recurrent head and neck cancer, which means that the person's cancer has come back after…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Chicago, Chicago, Illinois

    Run by

    University of Chicago

    See if you can join NCT05526924 on ClinicalTrials.gov

13. Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).

    This research is being done to see if it is safe to give investigational combination of study drugs (Pembrolizumab and IO102-103) before surgery to people with surgically resectable (removable) newly diagnosed or recurrent metastatic SCCHN. This will be done by watching participants closely for pos…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Northwestern Memorial Hospital, Chicago, Illinois

    Locations

    5 in total

    Run by

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    See if you can join NCT05977907 on ClinicalTrials.gov

14. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Chicago Comprehensive Cancer Center, Chicago, Illinois

    Locations

    21 in total

    Run by

    Clasp Therapeutics, Inc.

    See if you can join NCT06778863 on ClinicalTrials.gov

15. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Northwestern University Feinberg School of Medicine, Chicago, Illinois

    Locations

    39 in total

    Run by

    SystImmune Inc.

    See if you can join NCT05983432 on ClinicalTrials.gov

16. A Study of NX-1607 in Adults With Advanced Malignancies

    This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Chicago, Chicago, Illinois

    Locations

    17 in total

    Run by

    Nurix Therapeutics, Inc.

    See if you can join NCT05107674 on ClinicalTrials.gov